Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features
Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features
复制标题
DOI：
10.1038/modpathol.2012.240
复制
发表时间：
2013-06-01
期刊：
影响因子：
7.5
通讯作者：
Buchanan, Daniel D.
中科院分区：
文献类型：
--
作者：
Rosty, Christophe;Young, Joanne P.;Buchanan, Daniel D.
kras突变癌占所有结直肠癌的35-40%，但对其特征知之甚少。本研究的目的是研究kras突变的结直肠癌的病理和分子特征，并将其与其他癌症亚组进行比较。KRAS突变检测是在墨尔本合作队列研究的776例肿瘤中进行的。采用免疫组织化学和MethyLight技术评估o -6-甲基鸟嘌呤DNA甲基转移酶（MGMT）状态。微卫星不稳定性（MSI）表型和BRAF V600E突变状态来源于早期的研究。KRAS密码子12或密码子13突变存在于28%的结直肠癌中。与KRAS野生型癌相比，KRAS突变型癌更常见于残留息肉(38% vs 21%
KRAS-mutated carcinomas comprise 35-40% of all colorectal carcinomas but little is known about their characteristics. The aim of this study was to examine the pathological and molecular features of KRAS-mutated colorectal carcinomas and to compare them with other carcinoma subgroups. KRAS mutation testing was performed in 776 incident tumors from the Melbourne Collaborative Cohort Study. O-6-methylguanine DNA methyltransferase (MGMT) status was assessed using both immunohistochemistry and MethyLight techniques. Microsatellite instability (MSI) phenotype and BRAF V600E mutation status were derived from earlier studies. Mutation in KRAS codon 12 or codon 13 was present in 28% of colorectal carcinomas. Compared with KRAS wildtype carcinomas, KRAS-mutated carcinomas were more frequently observed in contiguity with a residual polyp (38 vs 21%; P